PT2620153T - Injecção de 5α-androstano-3β,5,6β-triol e método de preparação desta - Google Patents
Injecção de 5α-androstano-3β,5,6β-triol e método de preparação destaInfo
- Publication number
- PT2620153T PT2620153T PT118263615T PT11826361T PT2620153T PT 2620153 T PT2620153 T PT 2620153T PT 118263615 T PT118263615 T PT 118263615T PT 11826361 T PT11826361 T PT 11826361T PT 2620153 T PT2620153 T PT 2620153T
- Authority
- PT
- Portugal
- Prior art keywords
- beta
- androstane
- alpha
- alkyl
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010292234XA CN101961311B (zh) | 2010-09-21 | 2010-09-21 | 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2620153T true PT2620153T (pt) | 2018-07-18 |
Family
ID=43514490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT118263615T PT2620153T (pt) | 2010-09-21 | 2011-07-08 | Injecção de 5α-androstano-3β,5,6β-triol e método de preparação desta |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9161985B2 (pt) |
| EP (1) | EP2620153B1 (pt) |
| JP (1) | JP5750680B2 (pt) |
| KR (1) | KR101468153B1 (pt) |
| CN (1) | CN101961311B (pt) |
| AU (1) | AU2011304917B2 (pt) |
| BR (1) | BR112013005763B1 (pt) |
| CA (1) | CA2809646C (pt) |
| CY (1) | CY1120724T1 (pt) |
| DK (1) | DK2620153T3 (pt) |
| ES (1) | ES2677069T3 (pt) |
| HR (1) | HRP20181002T1 (pt) |
| HU (1) | HUE038230T2 (pt) |
| LT (1) | LT2620153T (pt) |
| PL (1) | PL2620153T3 (pt) |
| PT (1) | PT2620153T (pt) |
| RS (1) | RS57409B1 (pt) |
| RU (1) | RU2532354C1 (pt) |
| SG (2) | SG10201400723UA (pt) |
| SI (1) | SI2620153T1 (pt) |
| TR (1) | TR201809354T4 (pt) |
| WO (1) | WO2012037834A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101884638B (zh) * | 2010-07-09 | 2011-11-09 | 中山大学 | 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用 |
| CN103626818B (zh) | 2012-03-08 | 2016-03-30 | 广州市赛普特医药科技有限公司 | 雄甾-3β,5α,6β-三醇的晶型化合物及其制备方法 |
| CN103330946B (zh) * | 2013-05-29 | 2015-03-25 | 广州市赛普特医药科技有限公司 | 5α-雄甾-3β,5,6β-三醇注射剂其制备方法 |
| CN104288110B (zh) * | 2013-06-26 | 2017-05-10 | 广州市赛普特医药科技股份有限公司 | 5α‑雄甾‑3β,5,6β‑三醇注射剂及其制备方法 |
| WO2015047999A1 (en) * | 2013-09-26 | 2015-04-02 | Polyone Corporation | Sustainable poly(vinyl halide) mixtures for thin-film applications |
| CN113350359B (zh) * | 2017-12-29 | 2022-08-16 | 广州市赛普特医药科技股份有限公司 | 5α-雄甾-3β,5,6β-三醇在制备治疗出血性脑卒中药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2191576A (en) * | 1936-11-21 | 1940-02-27 | Soc Of Chemical Ind | 3,5,6-trihydroxy androstane and pregnane compounds |
| IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
| FR2668945B1 (fr) * | 1990-11-12 | 1993-02-19 | Theramex | Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus. |
| US5563131A (en) * | 1994-08-04 | 1996-10-08 | Pherin Corporation | Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
| US5824668A (en) * | 1996-11-07 | 1998-10-20 | Supergen, Inc. | Formulation for administration of steroid compounds |
| AU718232B2 (en) * | 1995-11-13 | 2000-04-13 | Supergen, Inc. | Improved formulation for administration of steroid compounds |
| US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
| CN1232539C (zh) * | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
| WO2004070048A1 (en) * | 2003-02-07 | 2004-08-19 | Pharmacia & Upjohn Company Llc | A microbial process to prepare 5-androsten-3beta, 7alpha, 15alpha-triol-17-one and related analogues |
| CN1706501A (zh) * | 2005-05-27 | 2005-12-14 | 沈阳药科大学 | 亲脂性药物环糊精包合物的制备方法 |
| CN101884638B (zh) * | 2010-07-09 | 2011-11-09 | 中山大学 | 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用 |
-
2010
- 2010-09-21 CN CN201010292234XA patent/CN101961311B/zh active Active
-
2011
- 2011-07-08 KR KR1020137006176A patent/KR101468153B1/ko active IP Right Grant
- 2011-07-08 EP EP11826361.5A patent/EP2620153B1/en active Active
- 2011-07-08 PL PL11826361T patent/PL2620153T3/pl unknown
- 2011-07-08 CA CA2809646A patent/CA2809646C/en active Active
- 2011-07-08 DK DK11826361.5T patent/DK2620153T3/en active
- 2011-07-08 TR TR2018/09354T patent/TR201809354T4/tr unknown
- 2011-07-08 HU HUE11826361A patent/HUE038230T2/hu unknown
- 2011-07-08 WO PCT/CN2011/076968 patent/WO2012037834A1/zh active Application Filing
- 2011-07-08 SI SI201131508T patent/SI2620153T1/en unknown
- 2011-07-08 SG SG10201400723UA patent/SG10201400723UA/en unknown
- 2011-07-08 PT PT118263615T patent/PT2620153T/pt unknown
- 2011-07-08 LT LTEP11826361.5T patent/LT2620153T/lt unknown
- 2011-07-08 RU RU2013105216/15A patent/RU2532354C1/ru active
- 2011-07-08 RS RS20180765A patent/RS57409B1/sr unknown
- 2011-07-08 BR BR112013005763-7A patent/BR112013005763B1/pt active IP Right Grant
- 2011-07-08 AU AU2011304917A patent/AU2011304917B2/en active Active
- 2011-07-08 ES ES11826361.5T patent/ES2677069T3/es active Active
- 2011-07-08 US US13/821,849 patent/US9161985B2/en active Active
- 2011-07-08 SG SG2013016126A patent/SG188393A1/en unknown
- 2011-07-08 JP JP2013527453A patent/JP5750680B2/ja active Active
-
2015
- 2015-08-28 US US14/839,869 patent/US9265837B1/en active Active
-
2018
- 2018-06-28 HR HRP20181002TT patent/HRP20181002T1/hr unknown
- 2018-06-29 CY CY181100681T patent/CY1120724T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269804A (en) | Conjugates of an active protein material and a method for their preparation | |
| ZA201206440B (en) | [5,6]heterocyclic compound | |
| EP2647644A4 (en) | RNA MODIFIED BY 2'-O | |
| EP2796442A4 (en) | ANALOG COMPOUND FROM A CAJANINE STRUCTURE, MANUFACTURING METHOD AND USE THEREOF | |
| GB201009237D0 (en) | New administration method | |
| EP2676965A4 (en) | ARYLGLYCOSIDE COMPOUND, MANUFACTURING METHOD AND APPLICATION THEREOF | |
| EP2530079A4 (en) | PHENYL-C-GLUCOSIDE DERIVATIVES, PREPARATION METHODS AND USES THEREOF | |
| HK1183558A1 (zh) | 同位素製備方法 | |
| HK1243004A1 (zh) | 輸液製劑 | |
| EP2573072A4 (en) | INDENOQUINOLONE COMPOUND, PROCESS FOR PREPARING THE SAME, AND USE THEREOF | |
| EP2725010A4 (en) | AMID CONNECTION, MANUFACTURING METHOD AND USE | |
| EP2594281A4 (en) | INSULIN LIPID COMPLEX, MANUFACTURING METHOD AND PREPARATION THEREFROM | |
| PT2620153T (pt) | Injecção de 5α-androstano-3β,5,6β-triol e método de preparação desta | |
| HK1180642A1 (zh) | 部件組裝方法 | |
| MY165626A (en) | 1,2,4,-triazolone derivative | |
| EP2789238A4 (en) | MICROBICIDAL COMPOSITION AND METHOD FOR OBTAINING THE SAME | |
| EP2634184A4 (en) | C-ARYLGLUCOSIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | |
| EP2524698A4 (en) | INSULIN PRODUCTION | |
| GB201009366D0 (en) | Ts 33 | |
| GB201008538D0 (en) | Ts 26 | |
| GB201008248D0 (en) | Ts 23 | |
| GB201007393D0 (en) | Ts 17 | |
| GB201007391D0 (en) | Ts 18 | |
| GB201002265D0 (en) | Ts 16 | |
| GB201002028D0 (en) | Ts 15 |